Current literature suggests that the coexistence of ALK fusion and other mutations might lead to alterations in epidemiological characteristics, clinical features, treatment options, drug response, prognosis, and survival of NSCLC patients. The gene discussed is ALK; the disease is non-small cell lung carcinoma.